US · YARW · BIOTECHNOLOGY
Yarrow Bioscience Inc (YARW) intrinsic value and stock valuation
$12.90as of 2026-11-21 · Mkt cap 648.29K
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Yarrow Bioscience Inc DCF and intrinsic value
InvestorsCraft values YARW with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from YARW’s statements →
Yarrow Bioscience Inc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $570K | $500K | $420K | $480K | $930K |
| Operating income | -$-29.75M | -$-43.64M | -$-29.26M | -$-34.3M | -$-38.91M |
| Net income | -$-26.48M | -$-39.83M | -$-28.45M | -$-23.21M | -$-73.33M |
| EPSd | -$-1.32B | -$-1.99B | — | — | — |
| Operating cash flow | -$-33.12M | -$-33.97M | -$-25.34M | -$-29.2M | -$-56.37M |
| Capital expenditure | $0.00 | -$-120K | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-33.12M | -$-34.09M | -$-25.34M | -$-29.2M | -$-56.37M |
| Total assets | $30.2M | $66.9M | $97.7M | $40.8M | $67.1M |
| Total debt | $0.00 | $100K | $210K | $0.00 | $350K |
| Net debt | -$-24.03M | -$-19.83M | -$-30.41M | -$-30.91M | -$-41.9M |
| Total equity | $27.8M | $52.1M | $88.7M | $31.2M | $48.6M |
| Cash and short-term investments | $29M | $61.5M | $93.3M | $30.9M | $42.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $570K | $500K | $420K | $480K | $930K |
| Cost of revenue | $20K | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $550K | $500K | $420K | $480K | $930K |
| Research and development expenses | $19.2M | $31M | $16.3M | $18.4M | $19.5M |
| Selling, general and administrative expenses | $11.1M | $13.2M | $13.4M | $16.4M | $20.3M |
| Other expenses | -$-20K | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $30.3M | $44.1M | $29.7M | $34.8M | $39.8M |
| Cost and expenses | $30.3M | $44.1M | $29.7M | $34.8M | $39.8M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $5.61M |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | $70K | $110K |
| Ebitda | -$-26.73M | -$-39.8M | -$-27.87M | -$-33.86M | -$-38.04M |
| Operating income | -$-29.75M | -$-43.64M | -$-29.26M | -$-34.3M | -$-38.91M |
| Total other income/expenses, net | $3.02M | $3.83M | $1.39M | $360K | -$-4.85M |
| Income before tax | -$-26.73M | -$-39.8M | -$-27.87M | -$-33.93M | -$-43.76M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $10K | $450K |
| Net income | -$-26.48M | -$-39.83M | -$-28.45M | -$-23.21M | -$-73.33M |
| Weighted average shares outstanding | $20K | $20K | $0.00 | $0.00 | $0.00 |
| Weighted average diluted shares outstanding | $20K | $20K | $0.00 | $0.00 | $0.00 |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $29M | $61.5M | $93.3M | $30.9M | $42.3M |
| Net receivables | $0.00 | $0.00 | $0.00 | $5M | $7.58M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $7.29M |
| Total current assets | $30M | $64.4M | $96M | $38.3M | $63.2M |
| Property, plant and equipment, net | $90K | $210K | $210K | $0.00 | $350K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $150K | $2.47M | $1.72M | $2.48M | $3.86M |
| Total assets | $30.2M | $66.9M | $97.7M | $40.8M | $67.1M |
| Accounts payable | $1.04M | $2.71M | $1.66M | $2.39M | $6.51M |
| Short-term debt | $0.00 | $100K | $120K | $0.00 | $350K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $2.4M | $14.8M | $7.54M | $9.35M | $18.4M |
| Long-term debt | $0.00 | $0.00 | $100K | $0.00 | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $0.00 | $1.41M | $210K | $0.00 |
| Capital lease obligations | $0.00 | $100K | $210K | $0.00 | $350K |
| Total liabilities | $2.4M | $14.8M | $8.95M | $9.56M | $18.4M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $10K |
| Retained earnings | -$-757.65M | -$-731.17M | -$-691.34M | -$-662.74M | -$-639.52M |
| Accumulated other comprehensive income (loss) | $0.00 | $20K | $30K | $0.00 | $0.00 |
| Total equity | $27.8M | $52.1M | $88.7M | $31.2M | $48.6M |
| Total investments | $4.98M | $41.6M | $62.6M | $0.00 | $0.00 |
| Total debt | $0.00 | $100K | $210K | $0.00 | $350K |
| Net debt | -$-24.03M | -$-19.83M | -$-30.41M | -$-30.91M | -$-41.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-26.74M | -$-39.83M | -$-28.45M | -$-23.21M | -$-73.33M |
| Depreciation and amortization | $20K | $0.00 | $0.00 | $70K | $110K |
| Stock-based compensation | $2.31M | $3.3M | $3.31M | $4.3M | $8.08M |
| Change in working capital | -$-8.19M | $5M | $60K | $2.28M | $4.78M |
| Accounts receivable | $4.21M | -$-900K | $410K | $11.2M | $7.71M |
| Inventory | $0.00 | $0.00 | $0.00 | $100K | $110K |
| Accounts payable | -$-12.31M | $6.01M | -$-560K | -$-8.68M | -$-2.67M |
| Net cash provided by operating activities | -$-33.12M | -$-33.97M | -$-25.34M | -$-29.2M | -$-56.37M |
| Investments in property, plant and equipment | $0.00 | -$-120K | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $5M | $15.7M | $0.00 |
| Net cash used for investing activities | $37.4M | $23.4M | -$-57.35M | $15.7M | $1.03M |
| Common stock issued | -$-140K | $0.00 | $82.8M | $1.47M | $76M |
| Common stock repurchased | $0.00 | -$-140K | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-140K | -$-140K | $82.4M | $1.65M | $39.8M |
| Net change in cash | $4.1M | -$-10.75M | -$-300K | -$-11.88M | -$-15.56M |
| Cash at end of period | $24M | $19.9M | $30.7M | $31M | $42.9M |
| Operating cash flow | -$-33.12M | -$-33.97M | -$-25.34M | -$-29.2M | -$-56.37M |
| Capital expenditure | $0.00 | -$-120K | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-33.12M | -$-34.09M | -$-25.34M | -$-29.2M | -$-56.37M |
Line items
Line items
Line items
About Yarrow Bioscience Inc
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
- CEO
- David Domzalski
- Employees
- 10
- Beta
- 2.01
Explore
Frequently asked questions
What is the intrinsic value of Yarrow Bioscience Inc (YARW)?
Yarrow Bioscience Inc (YARW) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is YARW undervalued?
YARW trades at a price of $12.90 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.